News

Natco Pharma's Hyderabad unit concludes USFDA inspection

21-Nov-2026 | 12:17

Natco Pharma announced conclusion of US FDA Inspection at its formulation plant located at Kothur, Hyderabad. 

The U.S. Food and Drug Administration (USFDA) conducted an inspection of the Company's Formulation manufacturing facility located in Kothur, Hyderabad, India, from 12 November to 20 November 2026.

Upon conclusion of the inspection, the Company received seven (7) observations in the Form-483. The Company believes that the observations are procedural in nature and is confident of addressing these observations comprehensively within stipulated timelines.